Does finerenone help kidneys in people without diabetes?
New in NEJM: Finerenone slowed kidney function decline in adults with chronic kidney disease without diabetes, reducing eGFR loss by 0.7 ml/min/1.73m² per year over 32 months versus placebo.
#KidneyDisease
doi.org/10.1056/nejmoa2604625
New in NEJM: Finerenone slowed kidney function decline in adults with chronic kidney disease without diabetes, reducing eGFR loss by 0.7 ml/min/1.73m² per year over 32 months versus placebo.
#KidneyDisease
doi.org/10.1056/nejmoa2604625
Finerenone in Persons with Chronic Kidney Disease without Diabetes.
New England Journal of Medicine · 11 new citations this week and rising on Discover.
jclub.com.au
November 5, 2026 at 7:02 AM
Does finerenone help kidneys in people without diabetes?
New in NEJM: Finerenone slowed kidney function decline in adults with chronic kidney disease without diabetes, reducing eGFR loss by 0.7 ml/min/1.73m² per year over 32 months versus placebo.
#KidneyDisease
doi.org/10.1056/nejmoa2604625
New in NEJM: Finerenone slowed kidney function decline in adults with chronic kidney disease without diabetes, reducing eGFR loss by 0.7 ml/min/1.73m² per year over 32 months versus placebo.
#KidneyDisease
doi.org/10.1056/nejmoa2604625
Trois études suggèrent que la finérénone pourrait élargir ses indications au-delà de l’IRC diabétique. Le traitement ralentirait le déclin de la fonction rénale et réduirait certains risques rénaux et cardiovasculaires.
➡️ https://l.whatsupdoc-lemag.fr/gj9
➡️ https://l.whatsupdoc-lemag.fr/gj9
November 7, 2026 at 8:30 AM
Trois études suggèrent que la finérénone pourrait élargir ses indications au-delà de l’IRC diabétique. Le traitement ralentirait le déclin de la fonction rénale et réduirait certains risques rénaux et cardiovasculaires.
➡️ https://l.whatsupdoc-lemag.fr/gj9
➡️ https://l.whatsupdoc-lemag.fr/gj9
Our latest BIDA Journal puts #Finerenone under the microscope. How successful is it really in treating patients with heart failure and diabetes? Go to tinyurl.com/n74mxfa9 #diabetesawarenessmonth #heart #heartfailure #cardiovascular #research
November 4, 2026 at 6:51 AM
Our latest BIDA Journal puts #Finerenone under the microscope. How successful is it really in treating patients with heart failure and diabetes? Go to tinyurl.com/n74mxfa9 #diabetesawarenessmonth #heart #heartfailure #cardiovascular #research
The biggest risk in pharma business development is making a decision with half the picture. Finerenone may look open across MENA, yet 15+ applications are reportedly waiting. Before investing, know who is already ahead of you.
November 2, 2026 at 7:15 AM
The biggest risk in pharma business development is making a decision with half the picture. Finerenone may look open across MENA, yet 15+ applications are reportedly waiting. Before investing, know who is already ahead of you.
(4) the ERA drugs - sparsentan and Atrasentan - are so unimpressive here - despite 30-40% proteinuria their GFR effect is similar to flozins or finerenone at much higher $$$$ cost
October 25, 2026 at 5:39 PM
(4) the ERA drugs - sparsentan and Atrasentan - are so unimpressive here - despite 30-40% proteinuria their GFR effect is similar to flozins or finerenone at much higher $$$$ cost
(5) cost
Cost and benefit have a very loose correlation
Flozins and prednisone are awesome here - and even finerenone looks like a bargain compared to the rest (unaffordable) price points
Cost and benefit have a very loose correlation
Flozins and prednisone are awesome here - and even finerenone looks like a bargain compared to the rest (unaffordable) price points
October 25, 2026 at 5:39 PM
(5) cost
Cost and benefit have a very loose correlation
Flozins and prednisone are awesome here - and even finerenone looks like a bargain compared to the rest (unaffordable) price points
Cost and benefit have a very loose correlation
Flozins and prednisone are awesome here - and even finerenone looks like a bargain compared to the rest (unaffordable) price points
#kidneywk Day 3 of simultaneous publications covered by #nephjc
Until the next time 👋
✍️ @nephroseeker.medsky.social @dramiliflores.bsky.social @nephromommy-akshu.bsky.social @hswapnil.medsky.social
www.nephjc.com/news/denver-...
Until the next time 👋
✍️ @nephroseeker.medsky.social @dramiliflores.bsky.social @nephromommy-akshu.bsky.social @hswapnil.medsky.social
www.nephjc.com/news/denver-...
Kidney Week in Denver: Day 3 — NephJC
Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
www.nephjc.com
October 25, 2026 at 2:17 PM
#kidneywk Day 3 of simultaneous publications covered by #nephjc
Until the next time 👋
✍️ @nephroseeker.medsky.social @dramiliflores.bsky.social @nephromommy-akshu.bsky.social @hswapnil.medsky.social
www.nephjc.com/news/denver-...
Until the next time 👋
✍️ @nephroseeker.medsky.social @dramiliflores.bsky.social @nephromommy-akshu.bsky.social @hswapnil.medsky.social
www.nephjc.com/news/denver-...
Operationalizing a multi-country OMOP-based analytical pipeline to characterize finerenone initiators in the FINEROD study: methods, implementation and reproducibility #OHDSISocialShowcase
Lead: Daloha Rodriguez Molina
Team listed on poster ⬇️
🔗 https://loom.ly/vSx6Bwo
#JoinTheJourney
Lead: Daloha Rodriguez Molina
Team listed on poster ⬇️
🔗 https://loom.ly/vSx6Bwo
#JoinTheJourney
October 21, 2026 at 6:01 PM
Operationalizing a multi-country OMOP-based analytical pipeline to characterize finerenone initiators in the FINEROD study: methods, implementation and reproducibility #OHDSISocialShowcase
Lead: Daloha Rodriguez Molina
Team listed on poster ⬇️
🔗 https://loom.ly/vSx6Bwo
#JoinTheJourney
Lead: Daloha Rodriguez Molina
Team listed on poster ⬇️
🔗 https://loom.ly/vSx6Bwo
#JoinTheJourney
Operationalizing a multi-country OMOP-based analytical pipeline to characterize finerenone initiators in the FINEROD study: methods, implementation and reproducibility #OHDSISocialShowcase
Lead: Daloha Rodriguez Molina
Team listed on poster ⬇️
🔗 https://loom.ly/vSx6Bwo
#JoinTheJourney
Lead: Daloha Rodriguez Molina
Team listed on poster ⬇️
🔗 https://loom.ly/vSx6Bwo
#JoinTheJourney
October 21, 2026 at 1:05 PM
Operationalizing a multi-country OMOP-based analytical pipeline to characterize finerenone initiators in the FINEROD study: methods, implementation and reproducibility #OHDSISocialShowcase
Lead: Daloha Rodriguez Molina
Team listed on poster ⬇️
🔗 https://loom.ly/vSx6Bwo
#JoinTheJourney
Lead: Daloha Rodriguez Molina
Team listed on poster ⬇️
🔗 https://loom.ly/vSx6Bwo
#JoinTheJourney
【フィネレノンでステロイド型MRAに比べ、1.5年で「死亡」が半減 [！] ？？TriNetXデータベース/ESC HF】Oct.19
HF診断歴なくSGLT2-i服用中のCKD合併2型DMで、フィネレノンを開始した724例とステロイド型MRA開始1.542例中、PSマッチ可能だった724×2例比較——
・18カ月間の「死亡」HRはフィネレノンで0.5 [！] の有意低値。
NNTは「42」。KM曲線は開始直後から乖離を開始。
抄録🔗 qr.paps.jp/sQAQO [PDF全文Free]
HF診断歴なくSGLT2-i服用中のCKD合併2型DMで、フィネレノンを開始した724例とステロイド型MRA開始1.542例中、PSマッチ可能だった724×2例比較——
・18カ月間の「死亡」HRはフィネレノンで0.5 [！] の有意低値。
NNTは「42」。KM曲線は開始直後から乖離を開始。
抄録🔗 qr.paps.jp/sQAQO [PDF全文Free]
October 21, 2026 at 10:30 PM
【フィネレノンでステロイド型MRAに比べ、1.5年で「死亡」が半減 [！] ？？TriNetXデータベース/ESC HF】Oct.19
HF診断歴なくSGLT2-i服用中のCKD合併2型DMで、フィネレノンを開始した724例とステロイド型MRA開始1.542例中、PSマッチ可能だった724×2例比較——
・18カ月間の「死亡」HRはフィネレノンで0.5 [！] の有意低値。
NNTは「42」。KM曲線は開始直後から乖離を開始。
抄録🔗 qr.paps.jp/sQAQO [PDF全文Free]
HF診断歴なくSGLT2-i服用中のCKD合併2型DMで、フィネレノンを開始した724例とステロイド型MRA開始1.542例中、PSマッチ可能だった724×2例比較——
・18カ月間の「死亡」HRはフィネレノンで0.5 [！] の有意低値。
NNTは「42」。KM曲線は開始直後から乖離を開始。
抄録🔗 qr.paps.jp/sQAQO [PDF全文Free]
New research from Daniela C González-Cruz and colleagues summarises evidence regarding the values, preferences, and perceived treatment burden of adults with type 2 diabetes when considering initiation of GLP-1 receptor agonists
https://bit.ly/4yfum4A
https://bit.ly/4yfum4A
Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review
Objectives To summarise existing evidence regarding the values, preferences, and perceived treatment burden of adults with type 2 diabetes when considering initiation of glucagon-like peptide-1 recept...
bmjmedicine.bmj.com
October 20, 2026 at 7:36 PM
New research from Daniela C González-Cruz and colleagues summarises evidence regarding the values, preferences, and perceived treatment burden of adults with type 2 diabetes when considering initiation of GLP-1 receptor agonists
https://bit.ly/4yfum4A
https://bit.ly/4yfum4A
Germany’s G-BA found no proven added benefit for finerenone in chronic heart failure. #HTA #Pharma #HealthEconomics https://www.mattheneus.com/editorial/g-ba-finerenone-heart-failure-final-no-added-benefit-finearts-hf-2026-10-15
October 17, 2026 at 12:04 PM
Germany’s G-BA found no proven added benefit for finerenone in chronic heart failure. #HTA #Pharma #HealthEconomics https://www.mattheneus.com/editorial/g-ba-finerenone-heart-failure-final-no-added-benefit-finearts-hf-2026-10-15
She contends at www.beyondbloodtests.org/info-for-pat... that it's mineralocorticoid antagonists, such as low-dose spironolactone (12.5 to 25 mg), or eplerenone for male patients, or the new non-steroidal mineralocorticoid antagonist finerenone.
October 17, 2026 at 9:39 AM
She contends at www.beyondbloodtests.org/info-for-pat... that it's mineralocorticoid antagonists, such as low-dose spironolactone (12.5 to 25 mg), or eplerenone for male patients, or the new non-steroidal mineralocorticoid antagonist finerenone.
Researchers followed 6,001 adults, average age 72, with the form of heart failure where the heart pumps normally but has grown stiff. Half took finerenone, a pill first approved for diabetic kidney disease, and half a matching placebo, on top of their usual medicines. Hospitalizations and heart…
A Kidney Drug Faced the Stiff-Heart Form of Heart Failure
fitnesshealthandnutrition.com
October 18, 2026 at 4:00 AM
Researchers followed 6,001 adults, average age 72, with the form of heart failure where the heart pumps normally but has grown stiff. Half took finerenone, a pill first approved for diabetic kidney disease, and half a matching placebo, on top of their usual medicines. Hospitalizations and heart…
Which therapy leads in kidney protection? A Bayesian network analysis compares SGLT2 inhibitors, semaglutide and finerenone. https://www.mattheneus.com/editorial/frontiers-diabetic-kidney-disease-sglt2-semaglutide-finerenone-bayesian-network-2026-10-09 #HTA #NMA #EvidenceSynthesis
October 11, 2026 at 4:04 PM
Which therapy leads in kidney protection? A Bayesian network analysis compares SGLT2 inhibitors, semaglutide and finerenone. https://www.mattheneus.com/editorial/frontiers-diabetic-kidney-disease-sglt2-semaglutide-finerenone-bayesian-network-2026-10-09 #HTA #NMA #EvidenceSynthesis
PRO/CON debate: nonsteroidal (finerenone) vs. steroidal (spironolactone/ eplerenone) mineralocorticoid receptor antagonists in CKD: progress, pragmatism, and remaining uncertainties ca. 2026 from @ckj-era.bsky.social
#Nephpearls #Cardiorenal #NephSky
👉 pubmed.ncbi.nlm.nih.gov/42682722/
#Nephpearls #Cardiorenal #NephSky
👉 pubmed.ncbi.nlm.nih.gov/42682722/
October 10, 2026 at 12:25 PM
PRO/CON debate: nonsteroidal (finerenone) vs. steroidal (spironolactone/ eplerenone) mineralocorticoid receptor antagonists in CKD: progress, pragmatism, and remaining uncertainties ca. 2026 from @ckj-era.bsky.social
#Nephpearls #Cardiorenal #NephSky
👉 pubmed.ncbi.nlm.nih.gov/42682722/
#Nephpearls #Cardiorenal #NephSky
👉 pubmed.ncbi.nlm.nih.gov/42682722/
Finerenone hit a pharmacokinetic/pharmacodynamic sweet spot in CKD. Also suggested by the need to use higher doses in heart failure trials. An effective drug is not created out of a MoA , but by the combo MoA + PK + PD (or MoA + ADME) @stephensenn.bsky.social @hswapnil.medsky.social
October 10, 2026 at 2:51 PM
Finerenone hit a pharmacokinetic/pharmacodynamic sweet spot in CKD. Also suggested by the need to use higher doses in heart failure trials. An effective drug is not created out of a MoA , but by the combo MoA + PK + PD (or MoA + ADME) @stephensenn.bsky.social @hswapnil.medsky.social
In the latest Primary Care Update podcast, @markebell.bsky.social and co-hosts talk about using an AI chat therapist, theta-burst stimulation for adults with major depressive disorder, finerenone in adults with CKD but not DM, and GLP-1 agonists & vision loss risk: podcasts.apple.com/us/podcast/e...
Episode 217: AI therapists, theta-bursts for depression, finerenone for CKD, and GLP-1s causing vision loss.
Podcast Episode · Primary Care Update · October 7 · 32m
podcasts.apple.com
October 9, 2026 at 4:06 PM
In the latest Primary Care Update podcast, @markebell.bsky.social and co-hosts talk about using an AI chat therapist, theta-burst stimulation for adults with major depressive disorder, finerenone in adults with CKD but not DM, and GLP-1 agonists & vision loss risk: podcasts.apple.com/us/podcast/e...
Advance Release In Brief: A New Indication for Finerenone (Kerendia) https://bit.ly/4AJu3S5
October 5, 2026 at 3:58 PM
Advance Release In Brief: A New Indication for Finerenone (Kerendia) https://bit.ly/4AJu3S5
Acute #eGFR Changes With #Finerenone Examined in a Prespecified Analysis of #FINEONE
#VisualAbstract by Cristina Popa
https://www.kireports.org/article/S2468-0249(26)03315-2/fulltext
#VisualAbstract by Cristina Popa
https://www.kireports.org/article/S2468-0249(26)03315-2/fulltext
October 5, 2026 at 1:00 PM
Acute #eGFR Changes With #Finerenone Examined in a Prespecified Analysis of #FINEONE
#VisualAbstract by Cristina Popa
https://www.kireports.org/article/S2468-0249(26)03315-2/fulltext
#VisualAbstract by Cristina Popa
https://www.kireports.org/article/S2468-0249(26)03315-2/fulltext
Sweden's TLV extends Kerendia (finerenone) reimbursement to heart failure with LVEF 40% or higher, broadening access beyond CKD. https://www.mattheneus.com/editorial/tlv-kerendia-finerenone-heart-failure-lvef-40-reimbursement-extension-2026-09-28 #HTA #HealthEconomics
September 30, 2026 at 8:02 AM
Sweden's TLV extends Kerendia (finerenone) reimbursement to heart failure with LVEF 40% or higher, broadening access beyond CKD. https://www.mattheneus.com/editorial/tlv-kerendia-finerenone-heart-failure-lvef-40-reimbursement-extension-2026-09-28 #HTA #HealthEconomics
Finerenone vs steroidal MRAs in CKD: different strengths, different roles. nsMRAs offer robust cardiorenal outcome data in albuminuric CKD, while spironolactone/eplerenone remain key for resistant HTN, proteinuria, & affordability. Patient-centered choice matters. #CKD #MRA
September 30, 2026 at 9:54 AM
【備忘】Sep.28
ESC HF誌に、フィネレノンのHF例腎保護作用をめぐる論説。FINEARTS-HFを注意深く再読。腎高リスク例に対する有効性・安全性にフォーカス。”a non-significant interaction test does not establish that the treatment effect is identical across strata”と指摘。
抄録🔗 x.gd/RsIlq [PDF全文Fee]
ESC HF誌に、フィネレノンのHF例腎保護作用をめぐる論説。FINEARTS-HFを注意深く再読。腎高リスク例に対する有効性・安全性にフォーカス。”a non-significant interaction test does not establish that the treatment effect is identical across strata”と指摘。
抄録🔗 x.gd/RsIlq [PDF全文Fee]
Does higher kidney risk justify more finerenone? Reappraising absolute benefit against the safety window of FINEARTS-HF
Abstract. Chronic kidney disease has long been viewed as a reason for caution when prescribing mineralocorticoid receptor antagonists (MRAs) in heart failu
x.gd
September 28, 2026 at 10:46 PM
【備忘】Sep.28
ESC HF誌に、フィネレノンのHF例腎保護作用をめぐる論説。FINEARTS-HFを注意深く再読。腎高リスク例に対する有効性・安全性にフォーカス。”a non-significant interaction test does not establish that the treatment effect is identical across strata”と指摘。
抄録🔗 x.gd/RsIlq [PDF全文Fee]
ESC HF誌に、フィネレノンのHF例腎保護作用をめぐる論説。FINEARTS-HFを注意深く再読。腎高リスク例に対する有効性・安全性にフォーカス。”a non-significant interaction test does not establish that the treatment effect is identical across strata”と指摘。
抄録🔗 x.gd/RsIlq [PDF全文Fee]
🚨 ~30% of people with Type 1 Diabetes develop chronic kidney disease.
On Sept 17, 2026, the FDA approved Bayer's finerenone (Kerendia®) for CKD in adults with T1D — the first new treatment for this group in 30+ years.
Follow for more diabetes research updates 🧵👇
#Diabetes #T1D #KidneyHealth
On Sept 17, 2026, the FDA approved Bayer's finerenone (Kerendia®) for CKD in adults with T1D — the first new treatment for this group in 30+ years.
Follow for more diabetes research updates 🧵👇
#Diabetes #T1D #KidneyHealth
September 24, 2026 at 7:27 AM
🚨 ~30% of people with Type 1 Diabetes develop chronic kidney disease.
On Sept 17, 2026, the FDA approved Bayer's finerenone (Kerendia®) for CKD in adults with T1D — the first new treatment for this group in 30+ years.
Follow for more diabetes research updates 🧵👇
#Diabetes #T1D #KidneyHealth
On Sept 17, 2026, the FDA approved Bayer's finerenone (Kerendia®) for CKD in adults with T1D — the first new treatment for this group in 30+ years.
Follow for more diabetes research updates 🧵👇
#Diabetes #T1D #KidneyHealth
An exploratory pooled analysis of two randomized trials, involving 12,990 people with type 2 diabetes and chronic kidney disease, found stage regression after 3 years in 11.4% on finerenone versus 7.4% on placebo ([JAMA Cardiology](pubmed.ncbi.nlm.nih.gov/42234437/)). (2/5)
September 23, 2026 at 3:05 PM
An exploratory pooled analysis of two randomized trials, involving 12,990 people with type 2 diabetes and chronic kidney disease, found stage regression after 3 years in 11.4% on finerenone versus 7.4% on placebo ([JAMA Cardiology](pubmed.ncbi.nlm.nih.gov/42234437/)). (2/5)